FLOT2 and renal carcinoma: We further assessed the expression of Flot2 in renal biopsies from patients with MCD (n=7), FSGS (n=8), MN (n=8), IgAN (n=5), and DN (n=6) compared with normal renal tissues from subjects with renal carcinoma (n=3) by immunohistochemistry (IHC) (Supplementary Figure S2).